Introduction {#s1}
============

The endocannabinoid system (ECS), consists of endogenous cannabinoids, the enzymatic machinery involved in their synthesis and degradation, and the G-protein-coupled cannabinoid receptors type 1 and 2 (CB1 and CB2; [@CIT0017]). This system has emerged as a major regulatory mechanism of several physiological and pathophysiological processes, including feeding behavior and energy balance, where ECS activation promotes energy storage ([@CIT0002], [@CIT0003]; [@CIT0016]). Central administration of cannabinoids increases food intake through CB1 activation ([@CIT0007]; [@CIT0024]). It is also known that feeding suppression induced by a cannabinoid receptor blockade has a major peripheral component through the involvement of either peripheral nerve terminals, a direct participation of sympathetic nervous system, ghrelin, or leptin ([@CIT0001]; [@CIT0020]). Moreover, rodents with diet-induced or genetic obesity show increased endocannabinoid hypothalamic levels ([@CIT0017]). Conversely, genetic or pharmacological CB1 silencing ([@CIT0025]; [@CIT0016]; [@CIT0019]) supresses food intake in lean and obese starved animals ([@CIT0017]). However, studies have shown that CB1 blockade decreases fat mass and body weight gain independently of changes in food intake, mainly through increased sympathetic outflow, mitochondrial biogenesis, and heat production, as well as fatty acid mobilization and oxidation ([@CIT0008]; [@CIT0014]; [@CIT0016]). As a result, CB1 blockade ameliorates obesity-related metabolic disorders ([@CIT0005]; [@CIT0018]; [@CIT0017]).

The endocannabinoid system is thought to regulate food intake, essentially by affecting eating motivation through the mesolimbic pathway ([@CIT0006]) and the hypothalamus ([@CIT0005]; [@CIT0024], [@CIT0025]; [@CIT0019]). Pharmacological modulation of the ECS regulates neuronal activity (in parallel to feeding behavior) in the paraventricular (PVH), ventromedial, and arcuate (ARC) nuclei of the hypothalamus, as well as in the dorsomedial nucleus and lateral hypothalamic area ([@CIT0025]; [@CIT0022]). Also, the endogenous cannabinoid ligand anandamide (arachidonylethanolamide) increases food intake through CB1 receptor activation when infused into the ventromedial nculei of the hypothalamus ([@CIT0007]). Within the hypothalamus, the CB1 receptor has been shown to colocalize with corticotropin-releasing hormone (CRH) and cocaine-amphetamine-regulated transcript (CART) neurons in the PVH ([@CIT0005]), suggesting a direct influence of endocannabinoids on hypothalamic neuropeptide expression. Accordingly, different studies have shown that the decrease in food intake induced by CB1 receptor antagonism is associated with increased CRH ([@CIT0025]; [@CIT0019]), α-melanocyte-stimulating hormone ([@CIT0025]), and CART ([@CIT0025]; [@CIT0019]) expression, as well as decreased neuropeptide Y (NPY) levels ([@CIT0025]; [@CIT0019]).

Interestingly, it has been demonstrated that chronic pharmacological treatment with CB1 receptor antagonists renders animals tolerant to their anorectic action ([@CIT0016]; [@CIT0019]). Thus, chronic CB1 receptor antagonism might lead to neuronal and neuropeptide changes different from those observed after acute treatments in rats ([@CIT0019]). Accordingly, previous data have shown no changes in feeding behavior in adult conditional mutants lacking CB1 receptor neuronal expression (CamK-CB1-KO) or in total CB1 receptor knockout (CB1-KO) adult mice ([@CIT0016]). In contrast, food intake is reduced in young CB1-KO mice ([@CIT0005]). Here, we analyzed the role of the CB1 receptor on feeding behavior and hypothalamic neuropeptides, using CamK-CB1-KO and CB1-KO mutant adult male mice fed a standard (SD) or high fat diet (HFD). Our data suggest that the lack of decreased food intake in both models, which are in contrast to those observed after CB1 receptor acute antagonism ([@CIT0019]), further highlights the relevance of neuronal plasticity in energy homeostasis. These data provide new clues for understanding how the cannabinoid system is involved in the regulation of food intake, which should aid further developments of new CB1 antagonists.

Methods {#s2}
=======

Animals {#s3}
-------

We used adult (8 weeks) male CB1-KO mice ([@CIT0005]; [@CIT0018]) and CaMK-CB1-KO mice and their wildtype (WT) littermates. In CaMK-CB1-KO mice, the CB1 receptor was deleted in forebrain neurons expressing the Ca2+/calmodulin dependent kinase IIa, while CB1 expression is maintained in cortical GABAergic interneurons and in cerebellar neurons ([@CIT0005]). Mutant animals were in a mixed genetic background, with a predominant C57BL/6N contribution (seven backcrosses). The experiments were performed in agreement with the International Law on Animal Experimentation and were approved by the University of Bologna and USC Local Ethical Committee and the USC Ethical Committee (Project ID 15010/14/006). We used 6--10 animals per group. Animals were fed either a SD containing 12.3 KJ/g (11% fat, 19% protein, 70% carbohydrate) or a HFD having 18.9 KJ/g (40% fat, 15% protein, 45% carbohydrate; both diets from Dottor Piccioni Lab).

Peripheral Treatment with CB1 Antagonist {#s4}
----------------------------------------

C57BL6 mice were treated intraperitoneally (i.p.; 4 hours) with either the CB1 antagonist AM281 (Tocris Bioscience; 3mg/Kg) or vehicle (dimethyl sulfoxide) after overnight fasting.

Serum Analyses {#s5}
--------------

Serum leptin concentrations were determined using a Mouse Leptin ELISA kit EZML-82K (Millipore). Ghrelin concentrations were measured using a Rat/Mouse Ghrelin (Total) ELISA kit EZRGRT-91K (Millipore) and peptide YY (PYY3-36) concentrations were determined using a Peptide YY (3-36; Rat, Mouse, Porcine, Canine) EIA Kit EK-059-04 (Phoenix Pharmaceuticals, Inc.).

*In Situ* Hybridization {#s6}
-----------------------

Specific oligonucleotides for agouti-related peptide (AgRP), CART, CRH, NPY, and proopiomelanocortin (POMC) detection were used ([Supplementary Table S1](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv011/-/DC1)). These probes were 3'-end labeled with ^35^S-α-dATP using terminal deoxynucleotidyl transferase (Amersham Biosciences). *In situ* hybridizations were performed as previously published ([@CIT0010], [@CIT0011]; [@CIT0009]; [@CIT0013]). The slides from all experimental groups from the same experiment (wildtype vs. knockout for each genotype and diet) were exposed to the same autoradiographic film. All sections (16 μm) were scanned and the specific hybridization signal was quantified by densitometry (ImageJ 1.33, National Institutes of Health). The optical density of the hybridization signal was determined and subsequently corrected by the optical density of its adjacent background. We used 6--10 animals/group and 16--20 sections/animal (4--5 slides with four sections/slide).

Statistical Analysis {#s7}
--------------------

Data are expressed as mean ± standard error of the mean. Statistical significance was determined by student's *t*-test. A *p*-value \< 0.05 was considered significant.

Results {#s8}
=======

Food Intake, Body Weight, and Hormonal Plasma Levels in Adult CB1-KO Mice {#s9}
-------------------------------------------------------------------------

When compared to WT littermates fed the SD ([Figure 1A](#F1){ref-type="fig"}) or HFD ([Figure 1B](#F1){ref-type="fig"}), CB1-KO mice showed a sustained decrease in body weight. Still, no differences in food intake were found between CB1-KO mice and their respective WT littermates during this period on either the SD ([Figure 1C](#F1){ref-type="fig"}) or HFD ([Figure 1D](#F1){ref-type="fig"}). The HFD did not impact circulating levels of ghrelin or PYY3-36, althought differences in ghrelin levels become significant when both genotypes are compared on a HFD. In keeping with the body weight data, a HFD did not induce a further increase in leptin levels in CB1-KO mice ([Supplementary Table S2](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv011/-/DC1)).

![Food intake, body weight, and hypothalamic neuropeptide expression in adult whole body CB1 null mice (CB1-KO) mice. (A and B) Body weight gain and (C and D) cumulative food intake between 8--20 weeks in CB1-KO mice under either a standard diet (SD; A and C) or high-fat diet (HFD; B and D). (E--H) Representative *in situ* hybridization autoradiographic images (left panels) and neuroptide mRNA levels (right panels) of anorexigenic (E and F) and orexigenic (G and H) neuropeptides, in CB1-KO mice under SD (E and G) and HFD (F and H). AgRP, agouti-related peptide; ARC, arcuate nucleus of the hypothalamus; CART, cocaine-amphetamine-regulated transcript; CRH, corticotropin-releasing hormone; DMH, dorsomedial nucleus of the hypothalamus; LHA, lateral hypothalamic area; NPY, neuropeptide Y; POMC, proopiomelanocortin; PVH, paraventricular nuclei of the hypothalamus. Data are expressed as mean ± standard error of the mean; n = 7--10 animals per experimental group. \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001 vs. wildtype (WT).](ijnppy_pyv011_f0001){#F1}

CB1 Antagonism in Mice Fed HFD {#s10}
------------------------------

Mice fed a HFD acutely (4 hours) and i.p. treated with the CB1 antagonist AM281 diplayed significantly hypophagia ([Supplementary Figure S1A](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv011/-/DC1)) with concominant increases in the expression of CART and POMC in the ARC ([Supplementary Figure S1B](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv011/-/DC1)).

Hypothalamic Neuropeptide Expression in CB1-KO {#s11}
----------------------------------------------

A significant decrease in the mRNA levels of CART and POMC was detected in the ARC of CB1-KO mice, both under SD (WT and KO n = 7; CART: *p* = 0.02; POMC: *p* = 0.03; [Figure 1E](#F1){ref-type="fig"}) and HFD (WT and KO n = 10; CART: *p* = 0.008; POMC: *p* = 0.03; [Figure 1F](#F1){ref-type="fig"}). CB1-KO mice showed a increase in AgRP mRNA levels, regardless of the diet (*p* = 0.029 in HFD; [Figure 1G](#F1){ref-type="fig"} and [1H](#F1){ref-type="fig"}), and a significant increase in NPY mRNA in SD (*p* = 0.027 in HFD; [Figure 1G](#F1){ref-type="fig"}).

Food Intake, Body Weight, and Hormonal Plasma Levels in Adult CaMK-CB1-KO Mice {#s12}
------------------------------------------------------------------------------

When compared to WT littermates fed a SD ([Figure 2A](#F2){ref-type="fig"}) or HFD ([Figure 2B](#F2){ref-type="fig"}), CaMK-CB1-KO mice showed a sustained, lower body weight. Similar to CB1-KO mice, no differences in food intake were found between CaMK-CB1-KO mice and their respective WT littermates during this period under either SD ([Figure 2C](#F2){ref-type="fig"}) or HFD ([Figure 2D](#F2){ref-type="fig"}). HFD did not impact PYY3-36 circulating levels but induced a non-significant trend towards decreased ghrelin levels (*p* = 0.09). In keeping with the body weight data, HFD did not induce increased leptin levels in CaMK-CB1-KO mice ([Supplementary Table S2](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv011/-/DC1)).

![Food intake, body weight, and hypothalamic neuropeptide expression in adult neuronal CB1 conditional null mice (CamK-CB1-KO) mice. (A and B) Body weight gain and (C and D) cumulative food intake between 8--20 weeks in CaMK-CB1-KO mice under either a standard diet (SD; A and C) or high-fat diet (HFD; B and D). (E--H) Representative *in situ* hybridization autoradiographic images (left panels) and neuroptide mRNA levels (right panels) of anorexigenic (E and F) and orexigenic (G and H) neuropeptides, in CaMK-CB1-KO mice under SD (E and G) and HFD (F and H). ARC, arcuate nucleus of the hypothalamus; LHA, lateral hypothalamic area; DMH, dorsomedial nucleus of the hypothalamus. Data are expressed as mean ± standard error of the mean; n = 6--8 animals per experimental group. \**p* \< 0.05 and \*\**p* \< 0.01 vs. wildtype.](ijnppy_pyv011_f0002){#F2}

Hypothalamic Neuropeptide Expression in CaMK-CB1-KO Mice {#s13}
--------------------------------------------------------

A significant decrease in CART and POMC mRNA levels was detected in the ARC of CaMK-CB1-KO mice as compared to their WT littermates fed either a SD (WT n = 7; KO n = 6; CART: *p* = 0.02; POMC: *p* = 0.04; [Figure 2E](#F2){ref-type="fig"}) or HFD (WT and KO n = 8; CART: *p* = 0.03; POMC: *p* = 0.03; [Figure 2F](#F2){ref-type="fig"}). These changes were independent of the diet. No differences were detected in AgRP or NPY mRNA expression in this animal model when subjected to either SD ([Figure 2G](#F2){ref-type="fig"}) or HFD ([Figure 2H](#F2){ref-type="fig"}).

Discussion {#s14}
==========

Despite the recognition of the hypothalamus as a key structure involved in the regulation of feeding by cannabinoids, the hypothalamic mechanisms mediating this effect are poorly understood. Here, we analyzed hypothalamic neuropeptide expression in CaMK-CB1-KO and CB1-KO adult mice, aiming at clarifying the absence of an anorectic response associated with a prolonged ECS blockade. Our data reveal a significantly decreased expression of anorectic neuropeptides, namely POMC and CART, in both CB1-genetic models, an effect that was independent of the diet. These molecular changes suggest that the lack of hypophagia is mediated by a compensatory mechanism, leading to decreased expression of anorectic signals within the hypothalamus. Thus, hypothalamic neuropeptide regulation would be an adaptative response, secondary to metabolic changes, as a strategy to find and/or keep a new energy balance while avoiding depletion of energetic stores.

As previously reported, our data show a lower body weight gain in both adult CaMK-CB1-KO and CB1-KO mice compared with their respective WT controls, with a more pronounced phenotype in CB1-KO mice ([@CIT0005]; [@CIT0016]). We also observed no effect of CB1 genetic deletion on feeding behavior in adult mice ([@CIT0005]; [@CIT0016]), suggesting that an adaptive tolerance to early hypophagia takes place ([@CIT0016]). This tolerance to anorectic stimuli was previously reported in long-term pharmacological studies with CB1 receptor antagonists ([@CIT0025]; [@CIT0019]).

The interaction between CB1 and the melanocortin system in regulating feeding is unclear ([@CIT0004]). Our data showed a diet-independent significant decrease in POMC mRNA levels in both CaMK-CB1-KO and CB1-KO mice compared to their respective WT littermates. Although some studies have reported no changes in POMC expression when administering the CB1 antagonist rimonabant ([@CIT0023]; [@CIT0021]), these molecular analyses were conducted after long-term rimonabant treatment when no more differences in eating behavior were found, suggesting that tolerance was reached ([@CIT0019]). Conversely, in relation to the modulation of hypothalamic neuropeptides under acute CB1 receptor antagonism, it has recently been demonstrated that a significant increase of α-melanocyte-stimulating hormone, causes a molecular change that is in agreement with the anorexia observed ([@CIT0019]). Thus, our data suggest that under prolonged CB1 silencing, the significant decrease in POMC mRNA may prevent the anorectic response observed in young animals ([@CIT0025]). Our data also reveal that, in parallel to the decrease in POMC levels, there is a significant decrease in mRNA expression levels of the anorexigenic precursor CART within the ARC of both CaMK-CB1-KO and CB1-KO mice. Similarity to POMC, CART suppression was observed irrespective of the type of diet. Decreased CART expression has been implicated in the orexigenic response to the CB1 agonist anandamide ([@CIT0005]). Accordingly, acute CB1 antagonism increases CART levels in the ARC ([@CIT0015]), and a pharmacological CB1 blockade is unable to suppress food intake in CART-deficient mice ([@CIT0025]), suggesting a critical role for CART in mediating the action of the ECS on food intake. Thus, the suppression in CART may contribute to the lack of hypophagia that characterizes these two animal models of genetic CB1 ablation.

We also detected a marked rise in ARC orexigenic neuropeptides, namely AgRP or NPY, in CB1-KO mice. Cumulative studies report conflicting results concerning the interaction between endocannabinoids and NPY. For example, NPY is overexpressed or suppressed in response to anandamide or rimonabant, respectively ([@CIT0015]). However, NPY-deficient mice maintain an intact anorectic response when treated acutely with a CB1 receptor antagonist, suggesting that the NPY system plays a minor role in determining the observed anorexia. Notably, the two CB1 null models used in this study display a common loss of anorexigenic neuropeptide expression, independently of ARC orexigenic neuropeptides, suggesting that the changes are mediated by central CB1 receptors. In this regard, it is interesting to note that ghrelin showed a non-significant tendency towards increased levels in total CB1-KO mice when compared with CaMK-CB1-KO mice. This difference became significant when both genotypes were fed a HFD. Given that AgRP and NPY are hypothalamic targets of ghrelin ([@CIT0010]; [@CIT0009]), it is possible that differences in basal ghrelin between genotypes account for the discrepancy in AgRP and NPY expression, a hypothesis that will require further investigation.

Previous studies showed increased PVH neuronal activity and CRH overexpression under acute pharmacological CB1 antagonism ([@CIT0025]; [@CIT0019]). The anorectic role of CRH is widely established, and cumulative data indicate that CRH overexpression could underlie the anorectic effect of acute CB1 antagonist administration ([@CIT0025]; [@CIT0019]). Consistently, hypophagic young CB1-KO mice show increased CRH mRNA levels, suggesting that CB1 receptor activation inhibits CRH expression ([@CIT0005]; [@CIT0015]; [@CIT0024], [@CIT0025]; [@CIT0019]). Consistent with the absence of an anorexigenic response in our animals, we failed to observe any substantial change in PVH or CRH expression. Thus, the absence of CRH upregulation, alongside decreased POMC and CART expression, may also contribute to failed hypophagia in adult mice.

In summary, our data indicate that food intake in adult mice under constitutive CB1 ablation is associated with a failure in the activation of anorexigenic signals in ARC neurons, such as POMC and CART, suggesting an adaptative response under sustained negative energy balance that may overrule early anorectic responses. These data identify impaired melanocortin and CART signaling in the hypothalamus as possible mediators of the resistance to hypophagia developed after long-term CB1 ablation. The similarities of the changes exhibited by both models of CB1-ablation clearly indicate that all the changes here reported are mediated by central CB1 receptors.

[SUPPLEMENTAL FIGURE S1.](http://ijnp.oxfordjournals.org/lookup/suppl/doi:10.1093/ijnp/pyv011/-/DC1) Food intake and hypothalamic neuropeptide expression after acute treatment with the CB1 antagonist AM281. **(A)** Food intake and **(B)** CART and POMC mRNA levels in the arcuate nucleus of the hypothalamus (ARC) of rats IP-treated with vehicle or the CB1 antagonist AM281. Data are expressed as mean ± SEM; n=6-8 animals per experimental group. \* and \*\* P\<0.05 and 0.01 *vs.* vehicle.
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